Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date (Ascending) Package Discontinuation Date Status
70518-3263-04 70518-3263 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 19, 2022 In Use
62332-0620-05 62332-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0621-17 62332-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0622-50 62332-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0620-05 46708-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0621-17 46708-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
46708-0622-50 46708-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
00310-4535-30 00310-4535 Tremelimumab IMJUDO 300.0 mg/15mL Immunotherapy Monoclonal Antibody CTLA-4 Intravenous Oct. 21, 2022 In Use
00310-4505-25 00310-4505 Tremelimumab IMJUDO 25.0 mg/1.25mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous Oct. 21, 2022 In Use
69339-0171-03 69339-0171 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0171-05 69339-0171 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0172-03 69339-0172 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0172-05 69339-0172 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
57894-0450-01 57894-0450 Teclistamab TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct. 25, 2022 In Use
71335-2181-01 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
71335-2181-02 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
71335-2181-03 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
51655-0933-04 51655-0933 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 25, 2022 In Use
00615-8440-05 00615-8440 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
00615-8440-39 00615-8440 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
69238-2122-09 69238-2122 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 27, 2022 In Use
51655-0008-20 51655-0008 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 31, 2022 In Use
70518-2138-04 70518-2138 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 31, 2022 In Use
00615-8438-39 00615-8438 PREDNISONE Prednisone 1.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 1, 2022 In Use

Found 10,000 results in 10 millisecondsExport these results